Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: ELL2

Summary for ELL2

Gene information	Gene symbol	ELL2
	Ensembl ID	ENSG00000118985
	Entrez ID	22936
	Gene name	elongation factor for RNA polymerase II 2
	Synonyms	MRCCAT1
	Gene type	protein_coding
	UniProtAcc	O00472

Top

Dataset with differentially expressed gene: ELL2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.28669	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.253647	2.48e-12
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	0.396183	2.05e-20
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.256283	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.457099	2.31e-32
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.331855	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.399446	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.454028	2.97e-08
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.295116	6.09e-03
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.373137	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	0.767623	4.24e-03
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.502345	1.89e-24
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.354192	0.00e+00

Top

Expression of ELL2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ELL2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating ELL2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ELL2	hsa-miR-548b-5p	93.3841	NM_012081
ELL2	hsa-miR-548aq-5p	93.3841	NM_012081
ELL2	hsa-miR-548y	93.3841	NM_012081
ELL2	hsa-miR-548c-5p	93.3841	NM_012081
ELL2	hsa-miR-548ae-5p	93.3841	NM_012081
ELL2	hsa-miR-562	93.0382	NM_012081
ELL2	hsa-miR-19b-3p	92.9449	NM_012081
ELL2	hsa-miR-19a-3p	92.9449	NM_012081
ELL2	hsa-miR-552-5p	92.8825	NM_012081
ELL2	hsa-miR-4724-5p	92.5787	NM_012081
ELL2	hsa-miR-4470	92.051	NM_012081
ELL2	hsa-miR-320c	91.8249	NM_012081
ELL2	hsa-miR-4429	91.8249	NM_012081
ELL2	hsa-miR-320b	91.8249	NM_012081
ELL2	hsa-miR-320a-3p	91.8249	NM_012081
ELL2	hsa-miR-320d	91.8249	NM_012081
ELL2	hsa-miR-4524a-5p	91.7272	NM_012081
ELL2	hsa-miR-4524b-5p	91.7272	NM_012081
ELL2	hsa-miR-1250-3p	91.006	NM_012081
ELL2	hsa-miR-203b-3p	90.984	NM_012081
ELL2	hsa-miR-516b-3p	90.1233	NM_012081
ELL2	hsa-miR-7162-5p	90.1233	NM_012081
ELL2	hsa-miR-516a-3p	90.1233	NM_012081
ELL2	hsa-miR-190a-3p	89.9375	NM_012081
ELL2	hsa-miR-3135b	89.9279	NM_012081
ELL2	hsa-miR-4519	89.4405	NM_012081
ELL2	hsa-miR-3973	89.4027	NM_012081
ELL2	hsa-miR-664b-3p	88.8423	NM_012081
ELL2	hsa-miR-579-3p	88.8423	NM_012081
ELL2	hsa-miR-548n	88.186	NM_012081
ELL2	hsa-miR-7856-5p	88.1568	NM_012081
ELL2	hsa-miR-4680-3p	87.3539	NM_012081
ELL2	hsa-miR-3140-3p	87.0164	NM_012081
ELL2	hsa-miR-29b-1-5p	86.9674	NM_012081
ELL2	hsa-miR-4801	86.9505	NM_012081
ELL2	hsa-miR-548an	86.4375	NM_012081
ELL2	hsa-miR-567	86.2255	NM_012081
ELL2	hsa-miR-551b-5p	86.1157	NM_012081
ELL2	hsa-miR-5093	85.8635	NM_012081
ELL2	hsa-miR-2115-5p	85.6344	NM_012081
ELL2	hsa-miR-4717-5p	85.466	NM_012081
ELL2	hsa-miR-4731-3p	85.3949	NM_012081
ELL2	hsa-miR-5696	85.2953	NM_012081
ELL2	hsa-miR-8063	85.2844	NM_012081
ELL2	hsa-miR-182-5p	85.0913	NM_012081
ELL2	hsa-miR-4712-5p	84.7032	NM_012081
ELL2	hsa-miR-770-5p	84.7032	NM_012081
ELL2	hsa-miR-6499-3p	84.6981	NM_012081
ELL2	hsa-miR-4789-3p	84.6342	NM_012081
ELL2	hsa-miR-9-3p	84.2984	NM_012081

Page: 1 2 3

Top

Motifs and transcription factors (TFs) regulating ELL2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ELL2	taipale_tf_pairs__ELK1_TEF_NSCGGAWNTTACGTAAN_CAP	ELK1; TEF (directAnnotation).
ELL2	transfac_pro__M06035	ZNF749 (directAnnotation).
ELL2	transfac_pro__M01861	ATF1 (directAnnotation).
ELL2	kznf__ZNF282_Imbeault2017_OM_RCADE	ZNF282 (directAnnotation).
ELL2	metacluster_52.11	ZNF184 (directAnnotation).
ELL2	transfac_public__M00039	CREB1 (directAnnotation).
ELL2	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
ELL2	cisbp__M04023	CREB1 (directAnnotation).
ELL2	transfac_pro__M00691	ATF1 (directAnnotation).
ELL2	transfac_pro__M04746	E2F1 (directAnnotation).
ELL2	taipale_cyt_meth__KLF3_NRCCGCAGCCCN_FL_meth_repr	KLF3 (directAnnotation).
ELL2	jaspar__MA1117.1	RELB (directAnnotation).
ELL2	transfac_pro__M08803	CREM (directAnnotation).
ELL2	metacluster_22.18	BACH2 (inferredBy_Orthology).
ELL2	metacluster_22.37	BACH1 (directAnnotation).
ELL2	metacluster_22.34	BACH2 (directAnnotation).
ELL2	metacluster_22.35	MAFK (directAnnotation).
ELL2	kznf__CTCF_Rhee2011.2_ChIP-exo	CTCF (directAnnotation).
ELL2	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
ELL2	transfac_pro__M00803	E2F1; E2F3; E2F4; TFDP1 (directAnnotation).
ELL2	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
ELL2	transfac_pro__M04916	TAF1 (directAnnotation).
ELL2	metacluster_30.4	BACH1; BACH1; MAFG; MAFG; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2 (directAnnotation).
ELL2	metacluster_111.5	E4F1; E4F1 (directAnnotation).
ELL2	transfac_pro__M04862	NRF1 (directAnnotation).
ELL2	transfac_pro__M06794	ZNF107 (directAnnotation).
ELL2	swissregulon__hs__UBP1	UBP1 (directAnnotation).
ELL2	taipale_cyt_meth__MLX_NNCAYGTGMYN_FL_meth_repr	MLX (directAnnotation).
ELL2	transfac_pro__M06235	ZNF267 (directAnnotation).
ELL2	transfac_pro__M04848	TAF1 (directAnnotation).
ELL2	swissregulon__hs__HMX1	HMX1 (directAnnotation).
ELL2	jaspar__MA0502.2	NFYB (directAnnotation).
ELL2	metacluster_143.19	PLAGL2; ZNF740 (directAnnotation).
ELL2	transfac_pro__M07078	BHLHE40 (inferredBy_Orthology).
ELL2	metacluster_162.4	NR1D1; NR1D1; NR1D1; NR1D1; NR1D2; NR1D2; NR2F6; RORA; RORB; RORB; RORC; RORC (directAnnotation).
ELL2	transfac_pro__M06597	ZNF775 (directAnnotation).
ELL2	transfac_pro__M07260	IKZF1 (directAnnotation).
ELL2	transfac_pro__M01835	KLF4 (directAnnotation).
ELL2	swissregulon__hs__MTA3	MTA3 (directAnnotation).
ELL2	metacluster_2.9	IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology).
ELL2	transfac_pro__M00801	ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM (directAnnotation). ATF7-NPFF (inferredBy_Orthology).
ELL2	tfdimers__MD00143	IKZF1; MZF1 (directAnnotation).
ELL2	homer__GGAAATTCCC_NFkB-p65-Rel	RELA (inferredBy_Orthology).
ELL2	transfac_pro__M06678	ZNF287 (inferredBy_Orthology).
ELL2	transfac_pro__M06404	ZNF497 (directAnnotation).
ELL2	hdpi__CREB1	CREB1 (directAnnotation).
ELL2	transfac_pro__M01239	RELA (directAnnotation).
ELL2	taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr	JUND (directAnnotation).
ELL2	transfac_pro__M05397	ZNF444 (directAnnotation).
ELL2	hdpi__TIMELESS	TIMELESS (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."